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Abstract
Background: This study seeks to describe inpatient antimicrobial use (AU) utilizing the
National Healthcare Safety Network-AU (NHSN-AU) framework among solid organ
transplant recipients (SOTr) within 12 months after transplant.
Methods: This cross-sectional study included SOTr ≥ 18 years of age who underwent transplantation from January 2015 to December 2016 at a Midwestern US
transplant center. Inpatient AU was followed for 12 months post-transplant. Hospital
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days present up to 12 months post-transplant, AU variables, and Clostridioides difficile
infection (CDI) occurrences were analyzed.
Results: The cohort of 530 SOTr included 225 kidney (42.5%), 171 liver (32.3%), 45
lung (8.5%), 40 heart (7.5%), 39 multivisceral (7.4%), seven small bowel (1.3%), and
three pancreas (0.6%) transplants. Total days of therapy (DOT) were 22 782 among
the cohort, with a median of 5 days [interquartile range [IQR], 1–12]. Lung and liver
transplants had the most total DOT (6571 vs. 5569 days), while lungs and small
bowels had the highest median DOT (13 [IQR, 2–56] vs. 12 [IQR, 2–31]). The facilitywide DOT/1000 days were lowest in pancreas and highest in lung transplants (5.3 vs.
428.1). Small bowel transplants received the most resistant-Gram-positive infection
and hospital-onset infection agents for facility-wide DOT/1000 days present. Pancreas
and kidney transplants accounted for the most high-risk CDI agents. CDI occurred in
34 patients, with kidney and liver transplants experiencing 13 each.
Conclusion: This study represents one of the first reports of AU in SOTr utilizing the
NHSN-AU framework. More studies are needed for further peer-to-peer comparison
of AU in this complex patient population.
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INTRODUCTION

Patient- and encounter-level analysis of AU was performed to align
with the NHSN-AU module. The accuracy of data was confirmed via a

Antimicrobial stewardship programs (ASPs) involving multidisciplinary

randomized chart review of 20 patients.

healthcare teams ensure patients receive the most appropriate antimi-

Antimicrobial use variables included DOT, facility-wide DOT per

crobial, route of administration, dose, and duration of therapy. ASPs

1000 patient days, antimicrobial-free days, and NHSN AU report-

aid in optimizing patient outcomes, minimizing adverse effects, and

ing targets of resistant Gram-positive infection agents, hospital-onset

preventing the development of antimicrobial resistance. Antimicro-

infection (HOI) agents, and high-risk CDI agents.2 Antimicrobial was

bial stewardship (AMS) has existed within patient care for decades;

defined as antibacterial or antifungal agents included in the NHSN-

however, support for establishing formal ASPs within hospital sys-

AU module.2 Antiviral agents used for the treatment of influenza are

tems escalated in response to the recognition of the necessity of

included in the NHSN-AU module but were excluded for the purposes

AMS by the Centers for Disease Control and Prevention (CDC) in

of this study. A day of therapy was defined as at least 1 administra-

2014 and the United States government in 2015.1 Moreover, to pro-

tion of a unique antimicrobial to a unique patient per calendar day.2

vide national antimicrobial benchmarking metrics and use comparison,

Facility-wide DOT per 1000 patient days were accounted for using

the CDC optimized the National Healthcare Safety Network (NHSN)

DOT divided by patient days of SOTr within 1 year of transplant mul-

as a method for institutions to participate in antimicrobial use (AU)

tiplied by 1000.2 Antimicrobial free days were accounted for by lack of

reporting. NHSN-AU serves as a surveillance resource that can provide

administration of an antimicrobial to a patient on a given hospital day.

actionable data for ASPs. Data input into NHSN is obtained directly

Hospital days were further described as median hospital days and the

from electronic medication administration record and/or bar-coding

number of encounters per transplant type was evaluated. Data were

medication record. The functionality of NHSN-AU is based on a vari-

analyzed using descriptive statistics via Microsoft Excel.

ety of metrics including but not limited to patient location, patient
days present, antimicrobial days of therapy (DOT), and classification
of antimicrobial categories.2 While the NHSN-AU supports the pro-

3

RESULTS

gression of ASP metric analysis and institution comparison, it does
not require or provide pathways for analysis of AU specifically in solid

The final cohort was comprised of 530 SOTr 225 kidney (42.5%), 171

organ transplant recipients (SOTr).

liver (32.3%), 45 lung (8.5%), 40 heart (7.5%), 39 multivisceral (7.4%),

A white paper from the American Society of Transplantation

7 small bowel (1.3%), and 3 pancreas (0.6%) transplants. Baseline char-

described the current landscape and identified opportunities for ASP

acteristics are displayed in Table 1. Patients were primarily white and

in SOTr.3 The SOT population is uniquely at risk for infections in the set-

male with a median age of 61 years. Overall, there were 1672 hospi-

ting of complex transplant surgery and immunosuppression. However,

tal encounters among the 530 SOTr within 12 months of transplant,

there is limited data on AMS practices in SOTr and hence no transplant-

with kidney (39.7%) and liver (30%) transplants comprising most of the

exist.3

Analyzing AU

encounters (Table 2). Total DOT for antimicrobials was 22 782 among

metrics within SOTr is essential to track the progression of AU in this

the cohort, with a median DOT of 5 days [interquartile range [IQR],

patient population and measure the effects of AMS efforts. This study

1–12]. Lung and liver transplants had the most total DOT (6571 days

aimed to describe local inpatient AU utilizing the NHSN-AU frame-

vs. 5569 days), while lungs and small bowels had the highest median

work among SOTr within 12 months of transplant at a Midwestern US

DOT (13 [IQR, 2–56] vs. 12 [IQR, 2–31]) (Table 2). Lung transplants

transplant center.

received the most antimicrobials for facility-wide DOT/1000 days

specific AMS metrics or benchmarks currently

present among the cohort (428.1), with pancreas transplants receiving
the least (5.3). Of the NHSN classes evaluated (resistant Gram-positive

2
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agents, HOI agents, and high-risk CDI agents) facility-wide DOT/1000
patient days were lowest within 1 month of transplant (172, 231, 173

This institutional review board approved (IRB #13476), cross-sectional

DOT/1000 patient days, respectively), increasing somewhat from 1–3

study included SOTr at least 18 years of age who underwent trans-

months post-transplant (275, 288, 216 DOT/1000 patient days), before

plantation from January 2015 to December 2016 at Henry Ford

significantly increasing 3–12 months post-transplant (380, 418, 292

Hospital, an academic medical center in southeast Michigan. Inpatient

DOT/1000 patient days). The greatest proportion of antimicrobial-

AU was followed for 12 months post-transplant. Patient demographics

free hospital days was observed for pancreas 29 (35.8%), liver 1463

and transplant type were identified using the institution’s transplant

(33.9%), and lung 1134 (33.3%) recipients.

database. Antimicrobial use variables, Clostridioides difficile infection

HOI broad-spectrum agents were the most prescribed class of

(CDI) occurrences, and hospital days present up to 12 months post-

the three NHSN-AU categories evaluated (292.8 DOT/1000 days),

transplant were obtained using Microsoft SQL Server 2019 version

followed by agents predominately used for resistant Gram-positive

15.0.4198.2. Henry Ford Hospital utilizes Epic for its electronic health

infections (e.g., methicillin-resistant S. aureus and vancomycin-resistant

record (EHR). Information related to transplant patients was obtained

enterococcus) (252.7 DOT/1000 days), then high-risk CDI agents

through an internal quality improvement database, which was incorpo-

(214.3 DOT/1000 days) (Table 2). HOI agents use was most frequent

rated into the EHR server and cross-referenced against the EHR data.

in small bowel, multivisceral, and lung transplants. Small bowel, lung,
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TA B L E 1

Baseline characteristics

period, as well as colonization with drug-resistant organisms from

Variable - N (%), median [IQR]

(n = 530)

Age, year

61 [52–69]

Sex, male

337 (63.6)

Race

pre-transplant antimicrobial exposure, when optimizing antimicrobial
regimens.4–6 To develop effective ASPs tailored to the SOT population, it is essential to track and disseminate metrics of antimicrobial
consumption and patterns of use, as well as potential harm such as
CDI and the emergence of antimicrobial resistance. Our study is novel

Asian

12 (2.3)

as it demonstrates the development of measurements of AU spe-

Black

157 (29.6)

cific to SOTr within the framework of NHSN-AU, utilizing available

Other

25 (4.7)

White

336 (63.4)

institutional analytics without the need for additional resources.
Additionally, a unique facility-wide DOT/1000 days present was
employed in this study instead of a specific location, for example, a

Transplant type

post-transplant unit. All analyses were limited to that of the SOTr

Heart

40 (7.5)

Kidney

225 (42.5)

Liver

171 (32.3)

Lung

45 (8.5)

transplant window. Furthermore, analyses for days present per organ

Multivisceral

39 (7.4)

type were conducted using total hospital days present for respective

Pancreas

3 (0.6)

Small bowel

7 (1.3)

cohort within 12 months of transplantation. Therefore, the days
present metric was limited to that of the hospital days present for the
cohort – excluding non-transplant inpatients and SOTr outside of the

organ types.
Kidney and liver transplants comprised 75% of our cohort. Despite
kidney transplants holding the most encounters (39.7%), this group

Charlson Comorbidity Index score

was only responsible for 249.3 facility-wide DOT /1000 days present

Overall

5 [3–7]

Heart

4 [2.25–6]

Kidney

4 [3–6]

Liver

7 [5–8]

Lung

3 [2–4]

group for facility-wide DOT/1000 days present at 428.1. It should be

Multivisceral

6 [5–8]

noted lung recipient median hospital days present were approximately

Pancreas

4 [4–5]

double that of any other transplant type. Lung and liver transplants

Small bowel

1 [0–2]

had significantly more DOT compared to the other transplant types.

among the cohort. (Table 2) Liver transplant recipients were the second
leading encounter group (30%) and were responsible for 362.8 facilitywide DOT/1000 days present. In contrast, lung recipients accounted
for only a small proportion of encounters (9.6%) but were the leading

Despite this, both groups retained >30% of their hospital days as

Abbreviations: IQR, interquartile range.

antimicrobial-free.
These data highlight the variability of antimicrobial consumption

and heart transplants received the most anti-resistant Gram-positive

and patterns of use within the SOT population reflecting the variables

therapy (Table 2). The use of high-risk CDI agents was relatively lower

unique to the organ transplanted. This information is important to help

compared to the other categories, and pancreas and kidney transplants

tailor ASP programs specifically to the type of organ transplanted.
This analysis contains several limitations. The time period of the

accounted for the most use within this sector.
Of the 530 SOTr, 34 patients experienced an episode of CDI, kidney

data 2015–2016 for this pilot study may be considered a limitation;
however, this period was chosen to establish baseline AMS metrics.

and liver transplants experienced the most cases at 13 each.

Since 2016, the institutional ASP implemented numerous quality initiatives to guide AU in SOTr. The creation of organ-specific transplant

4
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protocols by infectious diseases transplant providers, infectious diseases pharmacists, and organ-specific transplant teams now provides

The results of this study provide insight into AU metrics for SOTr at a

guidance for surgical prophylaxis, opportunistic infection prophy-

large transplant facility in southeastern Michigan from January 2015

laxis, and immunosuppression. Additionally, close teamwork with the

to December 2016. The study represents the first report of AU metrics

microbiology laboratory has provided pathways for stewardship inter-

in SOTr within the construct of NHSN-AU.

ventions including but not limited to utilizing nares MRSA screening, T2

Although institutional ASPs and NHSN-AU reporting are strongly

Candida assays, and Carba-R assays. The AMS team is assessing how

recommended by regulatory agencies in the United States, they

these interventions may have affected baseline AMS metrics in SOTr.

programs.3

ASPs also

The lack of inclusion of antiviral use and assessment of the prevalence

must account for variables unique to the SOT population including

of multidrug-resistant organisms among the cohort is also a limitation.

the type of organ transplanted, timing since transplantation, donor-

Consideration should be taken that the analysis accounted for both

derived infections, the intensity of immunosuppression, and presence

antimicrobial prophylaxis and treatment indications. Antimicrobial-

of catheters, drains, and stents in the immediate post-transplant

free days may be the result of prolonged dosing intervals (e.g., thrice

are not specifically mandated for transplant
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Multivisceral

1672

2298

15 350

611

81

1468

3407

4318

3167

5 [1–10]

7 [4– 23]

5 [3–10]

5 [1–11]

10 [3–25]

5 [1–12]

4 [1–6]

6 [2–19]

Median
hospital
days present
[IQR])

22 782

1147

81

2403

6571

5569

3827

3184

Antibiotic
DOT (days)

5 [1–12]

12 [2–31]

4 [2–12]

7 [1–18]

13 [2–56]

4 [1–12]

4 [1–7]

5 [1–7]

Median
DOT [IQR]

1484.2

74.7

5.3

156.5

428.1

362.8

249.3

207.4

Cohort
DOT/1000
daysa

4304 (28)

130 (21.3)

29 (35.8)

317 (21.6)

1134 (33.3)

1463 (33.9)

518 (16.4)

713 (31)

Antibiotic-free
days (%)

252.7

368.2

37

211.9

362.5

204

129.1

354.7

Resistant
Gram-positive
agent *
organ-specific
DOT/1000
daysb

292.8

407.5

308.6

371.3

371.6

280.5

135.8

334.2

HOI agent**
organ-specific
DOT/1000
daysb

214.3

222.6

284

252

183.2

177

268.4

227.2

CDI high-risk
agent***
organ-specific
DOT/1000
daysb
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Abbreviations: CDI, Clostridoides difficile infection; DOT, days of therapy; HOI, hospital-onset infection; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus.
a
Total days of antimicrobial therapy per organ type / total hospital days present of cohort x 1000.
b
Total antimicrobial category specific days/hospital days present of specific organ x 1000.
*Resistant Gram-positive infection agents: ceftaroline, daptomycin, linezolid, and vancomycin.
**Hospital Onset Infection agents: aminoglycosides (amikacin, gentamicin, and tobramycin), aztreonam, cefepime, ceftazidime, imipenem/cilastatin, meropenem, and piperacillin/tazobactam.
***High-risk CDI agents: cefepime, ceftazidime, ceftriaxone, ciprofloxacin, clindamycin, levofloxacin, and moxifloxacin.
(Agents included within NHSN AU reporting targets of resistant Gram-positive infection agents, hospital-onset infection agents, and high-risk CDI agents that are not mentioned in the analysis were excluded due
to zero administrations to the cohort within 12 months post-transplant).

Total

39 (2.3)

154 (9.2)

Lung

13 (0.8)

161 (9.6)

Liver

Pancreas

501 (30)

Kidney

Small Bowel

140 (8.4)

664 (39.7)

Heart

Encounters (%)

Hospital
days present
(days)

Outcomes by transplant type

Organ Type

TA B L E 2

4 of 5

weekly vs. daily) for agents such as sulfamethoxazole/trimethoprim
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CONCLUSION

This study displays a novel approach to analyzing AU in SOTr within 12
months of transplantation using NHSN-AU metrics. The availability of
these SOT population-specific metrics will help direct and assess ASP
quality initiatives and peer-to-peer comparison.
AUTHOR CONTRIBUTIONS
Conceptualization/Methodology: Sage B. Greenlee, Tommy J. Parraga Acosta, Charles T. Makowski, Rachel M. Kenney, Mayur

SUPPORTING INFORMATION

Ramesh, Jonathan D. Williams, and George J. Alangaden; Soft-

Additional supporting information can be found online in the Support-

ware/Validation/Analysis: Sage B. Greenlee, Tommy J. Parraga Acosta,

ing Information section at the end of this article.

and Charles T. Makowski; Manuscript Writing: SG, TP, RK, and GA;
Manuscript Editing/Review/Final Approval: Sage B. Greenlee, Tommy
J. Parraga Acosta, Charles T. Makowski, Rachel M. Kenney, Mayur
Ramesh, Jonathan D. Williams, and George J. Alangaden.

How to cite this article: Greenlee SB, Acosta TJP, Makowski
CT, et al. Bridging the gap: An approach to reporting
antimicrobial stewardship metrics specific to solid organ

ACKNOWLEDGMENTS
None

transplant recipients. Transpl Infect Dis. 2022;24:e13944.
https://doi.org/10.1111/tid.13944

13993062, 2022, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/tid.13944 by Henry Ford Health System, Wiley Online Library on [23/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

5 of 5

GREENLEE ET AL .

